Cathie Wood's ARK Innovation ETF (NYSEMKT: ARKK) is known for its investments in game-changing growth stocks backed by high-tech companies at the leading edge of science, making Ginkgo Bioworks (NYSE: DNA) a very typical holding.

Using a ruthlessly optimized symphony of robotics, genetic engineering, data science, and automated cell culture technologies, the company's approach to providing cell-based manufacturing services is entirely without precedent. And with multiple potentially disruptive innovations in play, it just might be a great investment over the coming years.

In fact, its shares might even double in value over the next three years, even if it doesn't undertake any additional new initiatives to expand its operations.

Continue reading

Source Fool.com